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Tegafur–uracil (UFT) plus leucovorin
s (LV, folinic acid) with alternating irinotecan and oxaliplatin were effective and well tolerated in
patients with metastatic colorectal cancer (mCRC) in a phase I study. This study expanded the maximum tolerated dose group.
Patients aged X18 years had histologically confirmed, inoperable, previously untreated, measurable mCRC. Patients received
irinotecan 180mgm
 2 on day 1, oxaliplatin 100mgm
 2 on day 15 and UFT 250mgm
 2 plus LV 90mg on days 1–21 every 28 days.
The phase I/II study comprised 45 patients, 29 at the maximum tolerated dose (MTD). The response rate in 38 evaluable patients
was 63% (95% confidence interval (CI): 49–80). Median time to progression and overall survival were 8.7 months (95% CI: 7.9–10.4)
and 16.8 months (95% CI: 9.6–25.3), respectively. In the MTD group, one patient had grade 3 leucopaenia; one had grade
3 neutropaenia; three had grade 3 diarrhoea; and one had grade 3 neurotoxicity. No hand–foot syndrome grade 41 was seen.
In total, 67% of eligible patients received second-line therapy. UFT plus LV with alternating irinotecan and oxaliplatin is an efficacious
first-line treatment for mCRC, with minimal neurotoxicity and hand–foot syndrome.
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Patients with unresectable metastatic colorectal cancer (mCRC)
have a poor prognosis in the absence of effective chemotherapy.
The foundation of treatment for these patients is 5-fluorouracil
(5-FU) with leucovorin
s (LV), either alone or in combination
with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI). Many patients
with mCRC receive only first-line treatment (Table 1), with
some refusing second-line therapy and preferring to preserve their
quality of life, whereas others are not offered this option as
they are considered unfit as a result of disease progression.
Optimising first-line treatment is essential in mCRC. As
exposure to three active agents, rather than second-line therapy
itself, appears to predict improved survival (Grothey and Sargent,
2005), ‘up-front’ administration of three effective drugs may be the
most effective way to improve outcomes. Consequently, several
groups have investigated the FOLFOXIRI combination (5-FU,
oxaliplatin and irinotecan) in patients with mCRC (Masi et al,
2004; Souglakos et al, 2006; Falcone et al, 2007). Results from
phase III studies have been conflicting, however, with Falcone
et al (2007) demonstrating better outcomes for patients treated
with FOLFOXIRI compared with FOLFIRI, and Souglakos et al
(2006) reporting no significant difference between the two
regimens. Nonetheless, extremely promising overall survival (OS)
rates were reported in these studies (22.6 months and 21.5 months,
respectively), and a triple-drug approach holds great promise,
provided the triplet regimen is tolerable.
Toxicity is a significant problem with 5-FU-based regimens.
Intravenous (i.v.) bolus 5-FU is associated with considerable
myelosuppression (Meta-Analysis Group In Cancer, 1998). Con-
tinuous infusion 5-FU, although less toxic, requires venous access
using a tunnelled central line and portable infusion pumps, which
are inconvenient for patients, while indwelling catheters can cause
infection and thrombosis (Puig-la Calle et al, 1996; Verso and
Agnelli, 2003). The oral fluoropyrimidine tegafur–uracil (UFT) is a
convenient and well tolerated alternative to i.v. 5-FU. In phase III
studies, UFT with LV had equivalent efficacy compared to that of
i.v. 5-FU/LV, but with significantly better tolerability (Carmichael
et al, 2002; Douillard et al, 2002). In both studies, UFT with LV
was associated with significantly fewer haematological adverse
events, including febrile neutropaenia, than bolus 5-FU/LV. In
addition, patients in the UFT with LV group had a significantly
lower incidence of stomatitis and other gastrointestinal events than
5-FU/LV. A number of small studies have shown that UFT can
be combined with oxaliplatin (Feliu et al, 2004; Rosati et al,
2005; Bennouna et al, 2006; Bajetta et al, 2007a) or irinotecan
(Mendez et al, 2005; Delord et al, 2007; Bajetta et al, 2007a), both
combinations being effective and well tolerated in first-line mCRC.
The present phase I/II study, SCOUT (study of CPT-11,
oxaliplatin, UFT triple therapy), evaluated the efficacy and
tolerability of UFT with LV plus alternating irinotecan and
oxaliplatin in chemonaive patients with mCRC. We hypothesised
that alternating oxaliplatin and irinotecan would allow patients to
benefit from concurrent treatment with all three drugs as soon as
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sthey were diagnosed with metastatic disease, while allowing
them to recover from adverse events associated with each drug
before it was administered again. Results from the phase I study
have been published in full (Sheikh et al, 2007). Here we
present results for the expanded group of patients treated at the
maximum tolerated dose (MTD) and overall results from the phase
I/II study.
MATERIALS AND METHODS
Study design and patients
This single-centre, open-label, non-randomised phase I/II
study was conducted at the Christie Hospital (Manchester, UK)
on patients with histologically confirmed, metastatic adeno-
carcinoma of the colon or rectum, with inoperable, measurable
metastatic disease. Inclusion and exclusion criteria have
been described previously (Sheikh et al, 2007). In brief, patients
were aged X18 years, had no prior chemotherapy for meta-
static disease and a World Health Organization performance status
of 0–2. All patients had adequate organ and haematological
function.
The trial was conducted with full approval of the local ethical
committee, according to accepted standards of good clinical
practice, and in agreement with the latest version of the
Declaration of Helsinki. All patients provided written informed
consent.
Treatment
In the phase I study, patients received irinotecan 180mgm
 2 as a
90min infusion on day 1 of the 28-day cycle, oxaliplatin 85–
100mgm
 2 as a 2h infusion on day 15 and UFT capsules 200–
300mgm
 2d
 1 taken orally with LV 90mgd
 1 in three divided
doses on days 1–21. The MTD was irinotecan 180mgm
 2,
oxaliplatin 100mgm
 2 and UFT 250mgm
 2 plus LV 90mg.
Prophylactic antiemetics (dexamethasone 8mg and ondansetron
8mg) were administered intravenously with the irinotecan and
oxaliplatin infusions and thereafter orally for 48h.
Chemotherapy was administered for at least 8 weeks (two cycles)
before radiological reassessment, unless a criterion for study
discontinuation was met. Patients remained on treatment until
clinical or radiological progression, the occurrence of unacceptable
or cumulative toxicity or withdrawal was requested by the patient
or investigator. Treatment was continued for a further 2 months in
patients with signs of clinical benefit (stable disease or complete or
partial response) up to 6 months. Selected patients could continue
treatment for longer than 6 months at the investigator’s discretion,
and could receive further treatment with the SCOUT regimen or
another treatment of the investigator’s choice. Re-treatment with
SCOUT was only allowed in patients who had not progressed
during the initial treatment period.
Dose reductions and delays
Chemotherapy was delayed by 1 week in patients with neutro-
paenia grade X2 or platelets o100 10
9l
 1 (o75 10
9l
 1 for
oxaliplatin). If there was more than one delay or if a delay lasted
X2 weeks, doses of irinotecan and oxaliplatin were reduced by
20% and the daily UFT dose was reduced by one capsule (100mg).
Treatment continued at the lower dose for subsequent cycles
unless further toxicity occurred. If a further delay for myelotoxicity
occurred, 50% reduction was made to the original irinotecan and
oxaliplatin doses. Withdrawal of the patient from the study was
considered if their performance status had deteriorated.
Delayed diarrhoea was treated early and aggressively with
loperamide, with the addition of oral ciprofloxacin if it persisted
for 424h. However, after grade 3/4 diarrhoea, treatment was
delayed until complete recovery, and then resumed at 80% of the
irinotecan dose and with the UFT daily dose reduced by one
capsule. If diarrhoea of any grade had not resolved by the next
cycle, treatment was delayed by 1 week. If further grade X3
diarrhoea occurred, irinotecan was reduced to 50% of the original
dose and the daily UFT dose was reduced by two capsules.
Oxaliplatin was omitted for grade X3 paraesthesia of hands or feet
and dysaesthesia in the throat. Any significant deterioration in
liver or renal function was investigated by ultrasound examination
to rule out reversible biliary or renal outflow obstruction.
Response and toxicity evaluation
Patients were assessed clinically every 14 days and a full blood
count and biochemistry profile performed. Serum tumour
carcinoembryonic antigen (CEA) measurements were performed
monthly if raised at baseline. Toxicities were recorded at 2-weekly
visits according to the National Cancer Institute Common Toxicity
Criteria (version 2) and the dose-limiting toxicities at 1 month,
that is, diarrhoea, lethargy and vomiting, used to decide the dose
escalation schedule during the phase I study, as reported
previously (Sheikh et al, 2007).
Radiological assessment by CT scan was performed after two
cycles using the Response Evaluation Criteria in Solid Tumors
(RECIST) (Therasse et al, 2000). All scans were performed by a
dedicated gastrointestinal radiologist who provided measurements
of marker lesions. From these measurements, response was
confirmed by two research fellows. In cases of disagreement, scans
were reviewed by the principal investigator. Only patients receiving
two full 28-day cycles were assessable for the primary endpoint,
that is, the objective response rate (ORR), defined as the number of
patients achieving a partial or complete response at 8 weeks.
Table 1 Patients receiving second-line therapy in randomised clinical studies (adapted from Grothey et al, 2004)
First-line regimen
Patients with second-
line therapy (%)
Patients administered
three active drugs (%)
Median overall
survival (months) Reference
Irinotecan+bolus 5-FU/LV 52 5 14.8 Saltz et al (2000)
Irinotecan+bolus 5-FU/LV 67 24 15.0 Goldberg et al (2004)
Irinotecan+CIV 5-FU/LV 39 16 17.4 Douillard et al (2000)
Irinotecan+AIO 56 52 20.1 Ko ¨hne et al (2005)
Irinotecan+CIV 5-FU/LV 81 74 21.5 Tournigand et al (2004)
FOLFOX4 58 30 16.2 de Gramont et al (2000)
FOLFOX4 75 60 19.5 Goldberg et al (2004)
FOLFOX6 62 74 20.6 Tournigand et al (2004)
FOLFOX7 73 61 21.2 Tournigand et al (2006)
AIO¼Arbeitsgemeinschaft fu ¨r Internistische Onkologie; CIV¼continuous intravenous infusion; FOLFOX¼5-FU/LV+oxaliplatin; 5-FU¼5-fluorouracil; LV¼Leucovorin
s.
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Patient characteristics
Overall, 45 patients were treated, 29 of whom received the MTD.
Patient demographics and clinical characteristics are shown in
Table 2. In total, seven patients did not receive two cycles of
SCOUT and were not evaluable for response assessment; four of
these patients were in the MTD group. The evaluable population
therefore comprised 38 patients in total and 25 patients treated at
the MTD. Overall, five patients were not assessable for time to
progression (TTP), two of whom were treated at the MTD (three
patients died before completing an assessment scan after two
cycles and two withdrew for psycho-social reasons). All patients
were assessable for toxicity and OS. A majority of patients had
multiple lesions; only six patients had disease confined to the liver.
Response to treatment
Response to treatment is shown in Table 3.
An ORR of 68% (95% CI: 46–85%) and a disease-control rate of
100% (95% CI: 86–100%) were observed in the 25 evaluable
patients who received the MTD. Median OS was 19.6 months in
29 assessable patients (95% CI: 15.5–27.2) (Figure 1A) and median
TTP was 8.5 months in 27 assessable patients (95% CI: 7.6–11.1)
(Figure 1B). One-year survival was 72.4% (95% CI: 52.3–85.1%)
and 2-year survival was 37.2% (95% CI: 13.2–61.8%).
The ORR in the 38 evaluable patients in the phase I/II study was
63% (95% CI: 46–78%), with a disease-control rate of 89% (95%
CI: 75–97%). After a median follow-up of 14.9 months, median OS
was 16.8 months (95% CI: 9.6–25.3) in 45 evaluable patients
(Figure 1C) and median TTP was 8.7 months (95% CI: 7.9–10.4) in
40 evaluable patients (Figure 1D). One-year survival was 62.2%
(95% CI: 46.4–74.6%) and 2-year survival was 38.7% (95% CI:
21.6–55.5%).
Liver resections were performed on three patients. One patient
with a partial response after four cycles underwent an R0 resection,
one patient who had stable disease after three cycles had an R1
resection and one patient who had 5 cycles and achieved a partial
response had an R1 resection. Another patient, who underwent
a total of 11 treatment cycles and achieved a partial response on a
re-challenge with SCOUT is being assessed for liver resection.
Tolerability
Tolerability data for the phase I cohort are detailed in our earlier
publication. In the MTD group, 138 UFT courses were prescribed
to the 29 patients, 16 of which were reduced by 1 capsule daily and
8 of which were reduced by 2 capsules daily; 21 patients (72%)
received UFT without a dose reduction, 13 of whom (45%)
received all 6 UFT cycles at full dose. A total of 139 doses of
irinotecan therapy were administered, 17 doses were reduced by
20% and 3 by 50%; 132 doses of oxaliplatin were administered,
9 were reduced by 20% and 5 by 50%. The median dose intensity
was 89% for both irinotecan and oxaliplatin after two cycles;
92% and 91% for irinotecan and oxaliplatin, respectively, after
four cycles; and 95% and 92% for irinotecan and oxaliplatin,
respectively, after six cycles.
SCOUT was well tolerated at the MTD, as shown in Table 4. One
patient developed grade 3 neutropaenia and another had grade 3
leucopaenia. One patient with a history of hypertension, atrial
fibrillation and type II diabetes had a grade 4 cardiac event and
died following a myocardial infarction before cycle four. Alopecia
and neurotoxicity were minimal: three patients (10%) had grade 2
alopecia and three (10%) had grade 2/3 neurotoxicity. Hand–foot
syndrome grade 41 was not observed.
Second-line therapy
After failure of first-line therapy, 24 out of the 29 patients (83%)
treated at the MTD were considered for second-line treatment; 3
patients had not progressed at the time of the analysis and a
further 2 patients were excluded as they were not assessable for
progression, as described above. Six patients (25%) were deemed
unfit to receive second-line therapy. Eighteen patients received
second-line therapy (Table 5). Nine patients (38%) resumed
SCOUT, eight of whom were assessable for response: one patient
had a complete response (13%); three had partial responses (38%);
one had stable disease (13%) and three had progressive disease
(38%). Therefore, the ORR to re-treatment with SCOUT in the
MTD group was 50% and the disease control rate was 63%. Twelve
patients received other second-line regimens, including capecita-
bine-, irinotecan- and oxaliplatin-based regimens, as detailed in
Table 5.
Table 2 Patient characteristics at baseline (patients treated at the MTD)
Characteristic Value
No. of patients 29
Median age (range) (years) 57 (40–73)
Sex, n (%)
Male 25 (86)
Female 4 (14)
Primary tumour site, n (%)
Colon 15 (52)
Rectum 9 (31)
Rectosigmoid 5 (17)
WHO performance status, n (%)
0 15 (52)
1 11 (38)
2 1 (3)
Unknown 2 (7)
Prior surgical resection, n (%)
Radical 9 (31)
Palliative 10 (34)
Defunctioned only 2 (7)
None 8 (28)
No. of measurable lesions (%)
1 1 (3)
2 7 (24)
X3 21 (72)
MTD¼maximum tolerated dose; WHO¼World Health Organization.
Table 3 Anti-tumour efficacy of SCOUT
Outcome, n (%)
Patients at all doses
(n¼45)
MTD patients
(n¼29)
Not assessable
a 74
Evaluable patients 38 25
Complete response, n (%)
b 00
Partial response, n (%)
b 24 (63) 17 (68)
Stable disease, n (%)
b 10 (26) 8 (32)
Disease control rate
(95% CI)
c
89 (75–97) 100 (86–100)
Progressive disease, n (%)
b 4 (11) 0
Objective response rate
(95% CI)
63 (46–78) 68 (46–85)
CI¼confidence interval; MTD¼maximum tolerated dose.
aPatients did not receive
two treatment cycles and were thus not assessable for response.
bBased on the
number of evaluable patients.
cComplete response+partial response+stable disease
rates.
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sIf patients treated at all doses are considered, 36 out of the 45
patients (80%) were considered for second-line therapy, 12 (33%)
of whom were deemed unfit for further chemotherapy. Twelve
(50%) of the 24 patients who received second-line chemotherapy
resumed SCOUT. Two of the additional three patients from the
phase I study who resumed SCOUT responded to the re-challenge
with stable disease, and one had progressive disease. Therefore, the
ORR to re-treatment with SCOUT chemotherapy in all patients
was 36% and the disease control rate was 64%.
Nine out of the 12 patients (75%) who received second-line
SCOUT went on to receive a third-line chemotherapy regimen,
as shown in Table 5.
Out of the remaining 12 patients who received second-line
therapies other than SCOUT, 3 (25%) went on to receive a third-
line agent (mitomycin C/capecitabine: n¼2; XELOX: n¼1).
DISCUSSION
Recent studies have demonstrated that triple-drug regimens
can improve survival and response in patients with mCRC. Many
of these regimens, however, can be associated with excessive
toxicities. Alternating therapy, in which only two out of the three
drugs are administered at one time, provides a means of delivering
three effective drugs while minimising toxicity. The results from
the present study confirm that alternating irinotecan and
oxaliplatin during treatment with UFT with LV allows patients to
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Figure 1 Kaplan–Meier curves for (A) overall survival (n¼29) and (B) time to progression (n¼27) for patients treated at the MTD, and (C) overall
survival (n¼45) and (D) time to progression (n¼40) for all patients in the phase I/II study.
Table 4 Grade 3/4 adverse events per patient treated at the MTD
(all cycles)
NCI-CTC grade, n (%) (N¼29)
Event 3 4
Haematological
Anaemia 0 0
Leucopaenia 1 (3) 0
Neutropaenia 1 (3) 0
Thrombocytopaenia 0 0
Non-haematological
Alopecia NA NA
Anorexia 0 0
Lethargy 1 (3) 0
Nausea 0 0
Vomiting 0 0
Diarrhoea 3 (10) 0
Constipation 0 0
AST elevation 1 (3) 0
Neuropathy 1 (3) 0
Hand–foot syndrome 0 0
Infection 0 0
Abdominal pain 2 (7) 0
Cardiac 0 1 (3)
AST¼aspartate aminotransferase; MTD¼maximum tolerated dose; NA¼not
applicable; NCI-CTC¼National Cancer Institute Common Toxicity Criteria.
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haematological toxicities often observed with such treatments.
The combination of UFT with LV plus irinotecan and oxaliplatin
was highly effective, with excellent ORRs that were consistent with
the phase I study results and better than those reported for UFT
with LV plus irinotecan (Mendez et al, 2005; Delord et al, 2007;
Bajetta et al, 2007a) or UFT with LV plus oxaliplatin (Feliu et al,
2004; Rosati et al, 2005; Bennouna et al, 2006; Bajetta et al, 2007a),
providing further support for the up-front treatment approach.
Particularly notable was the fact that all patients treated at the
MTD benefited from therapy, with partial responses in 68%
patients and stable disease in 32%. The OS of 19.6 months seen in
patients treated at the MTD was comparable with results obtained
for other triplet regimens (Table 1).
Alternating oxaliplatin and irinotecan every 2 weeks allowed
relatively high doses of both agents to be used without significant
toxicities. Alopecia and neurotoxicity, which are commonly
observed in patients treated with irinotecan and oxaliplatin, were
minimal in our patients. Grade 2 alopecia was observed in three
patients (7%) and only one patient had grade 3 neuropathy.
Another feature of this study was the very low incidence of grade
3/4 haematological toxicities. This is likely to be a result of the
alternating schedule, in which a 4-week gap between each dose of
irinotecan and each dose of oxaliplatin allowed patients to recover
from oxaliplatin- and irinotecan-induced toxicities before
each drug was administered again. Indeed, at the MTD, only one
patient had grade 3 neuropathy. Grade 3/4 toxicities were mainly
gastrointestinal, with grade 3 diarrhoea in 10% patients. The single
grade 4 adverse event observed at the MTD was an unrelated
cardiac event in a patient with a history of hypertension, atrial
fibrillation and type II diabetes. Hand–foot syndrome, a disturb-
ing and disabling condition that can impact the quality of life of
affected patients (Scheithauer and Blum, 2004), is often seen in
patients treated with 5-FU and capecitabine, but was not observed
at grades 41 in the present study. This study was small, however,
and larger studies would be required to allow definitive conclu-
sions to be drawn regarding the propensity of UFT to cause this
syndrome.
UFT is a convenient alternative to infusional 5-FU, as it does not
require the use of Hickman lines or pumps and therefore the
complications associated with these modes of administration can
be avoided (Puig-la Calle et al, 1996). Studies have shown that
patients prefer UFT to i.v. 5-FU regimens, with most patients citing
the convenience of oral treatment as a reason for this preference
(Borner et al, 2002; Rocha Lima and del Giglio, 2005). However,
patient preference is largely driven by tolerability, as shown by a
recent study comparing capecitabine with the Nordic 5-FU/LV
regimen (Pfeiffer et al, 2006). In that study, i.v. 5-FU was preferred
to oral capecitabine, primarily because capecitabine-treated
patients had a higher incidence of adverse events, including
diarrhoea and hand–foot syndrome, whereas the Nordic 5-FU
regimen was well tolerated.
One concern regarding the use of intensive up-front triple
therapy is that the choice of second-line treatment may be limited
when patients progress. This is not the case with SCOUT, as the
tolerability of the alternating regimen meant that most patients
(67% of those in the phase I/II study group) were able to receive
further treatment, including repeated courses of SCOUT.
Re-treatment with SCOUT, which occurred in 33% patients eligible
for second-line therapy, resulted in further complete and partial
responses. This is in agreement with a previous report that
first-line FOLFOXIRI (5-FU, oxaliplatin and irinotecan) did not
compromise the feasibility of second-line treatments (Masi et al,
2006). In that study, 76% patients received second-line therapy and
further responses were observed in 33% patients, similar to our
findings. By virtue of their disease being chemosensitive, most
patients (75%) who were suitable for second-line SCOUT went
on to receive a third-line regimen, in contrast to only 25% of
those who resumed alternate second-line chemotherapy. Again,
this lends support to the good tolerability of SCOUT as well as to
the concept that further alternate lines of chemotherapy are still
possible after SCOUT.
Other triple-drug regimens have been shown to result in
excellent ORRs and survival. Objective response rates of 43–72%
and OS of 21.5–28.4 months have been reported for FOLFOXIRI
(Masi et al, 2004; Souglakos et al, 2006; Falcone et al, 2007).
Variations in response and survival outcomes are likely to be a
result of differences in the regimens used, for example, the doses of
irinotecan, oxaliplatin and 5-FU/LV were higher in the study by
Falcone and colleagues. In addition, the characteristics of patients
entered into the study also differed: patients in the study by
Souglakos and colleagues were not required to be younger than
75 years and the proportion of patients with Eastern Cooperative
Oncology Group performance status 2 was considerably higher
(50% compared with 35% in the Hellenic Group study). The triple-
drug combination of capecitabine, oxaliplatin and irinotecan
(XELOXIRI) has also been investigated (Masi et al, 2007; Bajetta
et al, 2007b). Efficacy outcomes were good, with an ORR of 63%
and median OS of 23.5 months in the study by Bajetta and
colleages, and an ORR of 70% and median progression-free
survival of 9.2 months in the study by Masi and colleagues.
FOLFOXIRI and XELOXIRI, however, caused considerable
haematological toxicity, neurotoxicity and diarrhoea. Grade 3/4
neutropaenia appears to be a particularly common problem with
concurrent triple-drug therapy, although this was rare with the
SCOUT regimen (grade 3 neutropaenia occurred in only 3%
patients).
Others have used 5-FU- and capecitabine-based alternating
regimens with good results. Objective response rates of 46–54%
and OS of 18–18.7 months have been observed in alternating
Table 5 Second- and third-line therapy following SCOUT
Regimen
No. of patients,
n (%), at all
doses (N¼45)
No. of patients,
n (%), at MTD
(N¼29)
Second-line therapy
Eligible for second-line therapy
a 36 24
Resumed SCOUT 12 (33) 9 (38)
Mitomycin C/capecitabine 3 (8) 2 (8)
Irinotecan/cetuximab 3 (8) 3 (13)
Oxaliplatin/modified de
Gramont
1 (3) 1 (4)
Oxaliplatin/capecitabine 1 (3) 0
Capecitabine 1 (3) 0
Phase I trial 3 (8) 3 (13)
Unfit for further chemotherapy 12 (33) 6 (25)
No. of patients at all doses (N¼45)
Third-line therapy
Second-line SCOUT patients
eligible for third-line therapy
b
12
Resumed SCOUT 2
Mitomycin C/capecitabine 1
Irinotecan/cetuximab 1
Capecitabine 1
Phase I trial 4
Unfit for further chemotherapy 2
Not progressed on second-line
therapy
1
MTD¼maximum tolerated dose.
aExcludes patients who were not assessable for
progression and those who had not progressed at the time of the analysis.
bPatients
who received SCOUT as second-line therapy and were considered eligible for
further treatment; excludes patients who had second-line treatments other than
SCOUT.
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toxicity (Aparicio et al, 2005; Ferrari et al, 2005; Hebbar et al,
2006). Cassinello et al (2006) reported a somewhat lower ORR of
37% and OS of 16.4 months for a regimen comprising oxaliplatin
on day 1 with capecitabine on days 1–14 of a 21-day cycle,
followed by irinotecan on day 1 plus capecitabine on days 1–14 of
a second 21-day cycle. Nonetheless, this regimen was well
tolerated, providing further support for the improved tolerability
of alternating regimens.
Considerable debate surrounds the optimal approach to treating
patients with mCRC. Results from the CAIRO and FOCUS studies
suggest that first-line monotherapy followed by second-line
combination therapy is as effective as combination chemotherapy
in the first line followed by monotherapy (Koopman et al,
2007; Seymour et al, 2007). In contrast, OPTIMOX1 indicated
that intensive first-line therapy with prolonged maintenance treat-
ment and planned reintroduction of intensive therapy is a valid
approach to treatment (Tournigand et al, 2006). The OPTIMOX2
study has demonstrated, however, that a break in therapy between
intensive treatments cannot be recommended (Maindrault-Goebel
et al, 2007). The SCOUT approach avoids the need for
discontinuing oxaliplatin, although reducing treatment intensity
between full-dose courses may be attractive to some patients.
Several limitations of this study need to be considered. This was
a single-centre, non-randomised study, making direct comparisons
with other studies difficult, and the patient numbers were small. In
addition, this study did not include a targeted agent, such as
cetuximab or bevacizumab, and therefore the question whether
targeted agents might improve response and survival rates remains
unanswered. However, it can be argued that the first priority in
combination chemotherapy scheduling should be optimisation of
the three well-known, conventional, active chemotherapy agents in
mCRC. As stated by Saltz at ASCO in 2002, ‘we need all three
drugs. We have conflicting data about how to best use them, but,
clearly, we need to have them all available to our patients’.
Evaluation of the role of the targeted agents combined with a well-
tolerated and effective alternating regimen, like SCOUT, would be
the next key step to improve outcomes further. Such a study is
underway, in which the SCOUT regimen will be combined with
cetuximab (E-SCOUT).
In conclusion, UFT with LV plus alternating irinotecan and
oxaliplatin is an effective, well-tolerated treatment approach for
patients with mCRC. SCOUT results in high ORRs (63%, 95% CI:
49–80), respectable survival (median TTP and OS were 8.7 months
(95% CI: 7.9–10.4) and 16.8 months (95% CI: 9.6–25.3),
respectively), and the feasibility of second- and third-line
treatments. SCOUT is convenient for both patients and hospital
staff, as it avoids the need for tunnelled central lines and their
associated complications, translating into saving out-patient time,
in-patient admissions and clinical costs.
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